REXULTI® Tablets, a New Antipsychotic Drug, Launched in Japan

Otsuka Pharmaceutical Co., Ltd. today announces the launch in Japan of REXULTI® Tablets (chemical name is brexpiprazole) in 1 mg and 2 mg tablets for the treatment of patients with schizophrenia. REXULTI is already available to patients in the U.S., Canada and Australia.

Based on the efficacy of REXULTI in the treatment of schizophrenia, it is included on the Japanese National Health Insurance Drug Price List as of April 18.

Brexpiprazole, a novel compound discovered by Otsuka, is a serotonin-dopamine activity modulator (SDAM, a new mechanism of action) that acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and an antagonist at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity for these receptors as well as for noradrenaline alpha1B/2C receptors.

REXULTI Tablets will be marketed to healthcare institutions across Japan starting from today.